News

The United Kingdom has awarded Memory Health a patent for a proprietary brain health supplement developed to prevent and treat neurodegenerative disease. Also called Memory Health, the all-natural nutritional supplement is made especially for Alzheimer’s disease (AD) and dementia patients. The company is the sole licensee…

The National Institutes of Health (NIH) has awarded a $4.8-million grant to support a project designed to discover how the ApoE4 gene variant, a known genetic risk factor for late-onset Alzheimer’s disease, induces neurodegeneration. The apolipoprotein E (ApoE) proteins encoded by the APOE gene…

Physicians, industry representatives, and Alzheimer’s disease patients urged lawmakers in Washington to pass legislation they say will improve access to amyloid positron imaging tomography (PET) scans for the diagnosis, research and treatment of Alzheimer’s. The Medical Imaging & Technology Alliance(MITA), the Council on…

A Phase 1b trial has started dosing Alzheimer’s patients with Alector’s candidate immune system-targeting therapy, called AL003, to evaluate its safety and tolerability, the company has announced. AL003 is an antibody which targets sialic acid binding Ig-like lectin 3 (SIGLEC 3, also known as CD33). SIGLEC 3 is…

Patients with inflammatory diseases such as rheumatoid arthritis or psoriasis have a higher risk of developing Alzheimer’s disease, which can be reduced by treatment with tumor necrosis factor (TNF) inhibitors. That finding, “Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Rheumatoid…

Researchers have found large deposits of aluminum and amyloid-beta — the protein that forms toxic aggregates in the brain and is thought to be involved in the onset of Alzheimer’s disease — in the same brain regions of patients with familial Alzheimer’s. Their findings point towards a…

The Alzheimer’s Foundation of America (AFA) will begin its annual trek across the United States next month to raise disease awareness, promote early detection, and connect communities through education. Now in its fourth year, the 2020 Educating America Tour will make its first stop in Albuquerque, New…

The U.S. Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for Adlarity — Corium’s once-weekly transdermal (skin) patch delivering donepezil — to treat dementia in Alzheimer’s disease. The FDA’s decision on whether or not to approve Adlarity is expected by July…

Soybean oil, an increasingly common cooking oil, especially in the United States, can cause changes in the brain that could be linked to diabetes, inflammation, and brain disorders, an early study in mice suggests. This oil, a type of polyunsaturated fat, is used to fry fast foods, added to…

Certain patterns of brain activity can predict early on the probability of cognitive decline in young mice at high genetic risk of developing Alzheimer’s disease, a study has found. The findings, “Early Hippocampal Sharp-Wave Ripple Deficits Predict Later Learning and Memory Impairments in an Alzheimer’s Disease…